Norway vs Sweden: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Norway
95.0%
in 2025
Sweden
95.0%
in 2025
Norway rank
37th
Sweden rank
37th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Norway
- Sweden
How they compare
Norway currently reports 95.0% against 95.0% in Sweden, a difference of 0.0%.
The two have swapped places 3 times across 18 shared years of data; in 2008 it was Norway ahead.
Norway ranks 37th and Sweden ranks 37th of 192 countries.
Across the 3 decades both report, Norway averaged higher in 2 and Sweden in 1.
Head to head by decade
| Decade | Norway | Sweden | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 88.5% | 79.0% | 9.5% | Norway |
| 2010s | 93.0% | 97.5% | 4.5% | Sweden |
| 2020s | 95.3% | 95.2% | 0.2% | Norway |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Norway or Sweden?
- Norway, at 95.0% against 95.0% in Sweden as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Norway and Sweden?
- 0.0%, with Norway ahead.
- How many years of comparable data are there for Norway and Sweden?
- 18 years are reported by both, from 2008 to 2025.
- How do Norway and Sweden rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Norway ranks 37th and Sweden ranks 37th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.